Resonance Health Ltd (ASX:RHT) Share Price

Company Profile

Business description
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group’s core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Contact
141 Burswood Road
Level 1
Burswood
PerthWA6100
AUS
T: +61 892865300
https://www.resonancehealth.com
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2026
Employees
18

Recommended

High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.

Mark Taylor | 21 April 2026

John Ternus, Apple’s hardware chief, will take up the role in September.

William Kerwin, CFA | 21 April 2026

Our view as China’s steel production drops.

Jon Mills, CFA | 21 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,084.70	40.50	-0.44%
CAC 40	8,235.72	95.32	-1.14%
DAX 40	24,270.87	146.93	-0.60%
Dow JONES (US)	49,149.38	293.18	-0.59%
FTSE 100	10,498.09	110.99	-1.05%
HKSE	26,133.61	353.87	-1.34%
NASDAQ	24,259.96	144.43	-0.59%
Nikkei 225	59,531.56	182.39	0.31%
NZX 50 Index	12,945.60	13.27	0.10%
S&P 500	7,064.01	45.13	-0.63%
S&P/ASX 200	8,856.20	40.60	-0.46%
SSE Composite Index	4,101.00	15.92	0.39%